<prompt> Pembrolizumab isCTLA4 inhibitorMonoclonal antibody against PDL1 receptorMonoclonal antibody against PD1 ligandMonochonal antibody against CDK416  <response>: Pembrolizumab and Nevolumab are monoclonal antibodies against PDL1 receptor used in BRAF -ve malignant melanoma. 